Amsterdam UMC proudly presents new spin-off Kling BioTherapeutics
November 18, 2021Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a
novel discovery platform and a robust pipeline of first in class oncology antibodies. Amsterdam UMC has partnered with U.S.-based venture capital firm Time BioVentures to build Kling, and is excited by the company’s rapid progress in attracting a world-class management team of seasoned drug development executives with impressive track records bringing breakthrough products to patients. The company’s offices and labs are located on Amsterdam UMC’s Meibergdreef campus.
More news
Funding from KWF for palliative cancer patients in meaning-making at home
The diagnosis of incurable cancer profoundly disrupts patients’ lives, often causing existential crises and a sense of lost purpose. The KWF-funded project “In Search of Stories” (ISOS) aimed to support these patients by partnering them with spiritual counsellors and professional artists. This co-creation process proved highly beneficial. New funding from KWF Dutch Cancer Society supports […]
News
Impact in education and beyond: VU researcher Laura Rupp secures Comenius Leadership Fellow grant
Laura Rupp has been awarded the Comenius Leadership Fellow grant for a three-year period. This grant of 500,000 Euros, will fund a project titled “Global English and International Dutch on the VU Campus”. Over the years, Rupp has successfully reached more than 100,000 people online worldwide, teaching how to understand diverse English accents and speak […]
News
Max Nieuwdorp’s innovative research on gut microbes: a path to combat fatty liver disease
Internist Max Nieuwdorp, of Amsterdam UMC, discovered a few years ago that the microorganisms in the intestines of many overweight people produce alcohol to an increased extent. Breaking down excessive alcohol leads to fatty liver disease, which in turn poses a risk of serious conditions such as diabetes and cardiovascular disease. Nieuwdorp has now received an ERC Advanced Grant of 2.5 million euros for a major study into the underlying causes of this excessive alcohol production.
News